# Original Article

# Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma

Zhen You<sup>1</sup>, Li-Ping Chen<sup>2</sup>, Hui Ye<sup>3</sup>

## **ABSTRACT**

**Objective:** To identify the risk factors for the presence of microvascular invasion (MVI) in patients with solitary small hepatitis B related hepatocellular carcinoma (HCC).

*Methods:* The data of 215 patients who underwent liver resection between 2008 and 2011 at our hospital were reviewed. MVI was confirmed on pathological examination in 41 patients. Preoperative risk factors for MVI were analyzed using uni- and multi-variate analyses.

Results: In the multivariate analysis, alpha-fetoprotein (AFP) greater than 400 ng/mL, tumor size and hypersplenism were independently associated with MVI. Receiver operating curve (ROC) analysis suggested the best cut-off value for tumor size was greater than 3.1 cm. The ROC curve analysis further identified patients with more than one above-mentioned risk factor may suffer from MVI with 75.6% sensitivity and 75.3% specificity. The recurrence-free and long-term survival rates of patients with MVI were significantly lower than patients without MVI.

**Conclusions:** Patients with MVI may suffer from poor outcomes. AFP greater than 400 ng/mL, tumor size and hypersplenism were preoperative predictors of MVI in patients with solitary small hepatitis B related HCC.

**KEY WORDS:** Hepatocellular carcinoma, Microvascular invasion, Predictor.

**Abbreviations:** Alpha-Fetoprotein (AFP), Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI), Receiver Operating Curve (ROC).

doi: http://dx.doi.org/10.12669/pjms.302.4652

# How to cite this:

You Z, Chen LP, Ye H. Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma. Pak J Med Sci 2014;30(2):331-334. doi: http://dx.doi.org/10.12669/pjms.302.4652

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### INTRODUCTION

Hepatocellular carcinoma is the sixth most common cancer and third most frequent cancer-related death in the worldwide.<sup>1</sup> Owning to the highly

- 1. Zhen You,
- 2. Li-Ping Chen,
- B. Hui Ye.
- 1-3: Division of Biliary Surgery, West China Hospital of Sichuan University, Chengdu (610041), China.

Correspondence:

Hui Ye, Division of Biliary Surgery, West China Hospital of Sichuan University, Chengdu (610041), China. Email: schxyz123@163.com

Received for Publication: November 25, 2013
 Accepted for Publication: January 15, 2014

prevalence of hepatitis B infection, the incidence of HCC in China alone accounts for about 55% cases in the worldwide.<sup>2</sup> Liver resection is perceived as a curative treatment for HCC in cirrhotic patients with good functional liver reserves. However, many risk factors may contribute to the postoperative recurrence after curative liver resection, such as tumor size, tumor numbers, high preoperative AFP level and so forth.<sup>3,4</sup> Microvascular invasion (MVI) is a strong prognostic factor for HCC after liver resection, even after liver transplantation. A number of investigations suggested MVI impact significantly on long-term and recurrence-free survivals after liver resection and transplantation.<sup>3,5</sup> The cancer cells may have spread via the vasculature before liver resection or transplantation for HCC in patients with MVI.6 Macrovascular invasion can be

detected by preoperative imaging, however, different to macrovascular invasion, detection of MVI using preoperative radiological imaging still remains a difficulty. Histological examination is still the only accurate method for assessing MVI until now. Although previous investigations indicated tumor size may be a predictive factor for MVI, which contributes to MVI for patients with small HCC is still unclear. Accordingly, we retrospectively reviewed our data to evaluate the possible risk factors for MVI in patients with small HCC.

## **METHODS**

Study group: The data of patients with single small HCC (no more than 5 cm in diameter) who underwent liver resection from 2008 to 2011 at our hospital were reviewed. HCC and microvascular invasion were confirmed by pathological examination after liver resection. According to the presence of MVI, patients were divided into two groups. Group MVI(+), which consisted of patients with MVI; group MVI(-), which consisted of patients without MVI. Hypersplenism was defined as follow: platelet counts less than  $80 \times 10^9/L$  and/or white blood cell counts less than  $3\times 10^9/L$ . This study was approved by the ethics committee of West China Hospital.

Surgical procedure: Patients who received liver resection at our hospital should have preoperative liver function of Child-Pugh class A. Hemihepatic vascular occlusion was the primary technique performed to reduce intraoperative bleeding. The Pringle manoeuver was considered as a back-up strategy. A CUSA Excel<sup>TM</sup> device was utilized for liver transection. Drainage was routinely placed in the subphrenic cavity before closure.

Follow-up: After operation, all patients were monitored by serum AFP examination, visceral ultrasonography or CT or MR imaging and chest radiography every three months. Bone scintigraphy was performed whenever HCC recurrence was suspected. Recurrence was defined as positive imaging findings compared to preoperative examination values and newly rising tumor marker (AFP) values or confirmed by biopsy or resection.<sup>11</sup>

*Statistical analysis:* Continuous variables were presented as the mean±SD. Categorical variables were analyzed using the chi-square test or Fisher's exact test, whereas one-way analysis of variance was used to analyze continuous variables. Independent risk factors were identified by logistic regression. Factors significant at a P < 0.10 in the univariate analyses were involved in the multivariate

analyses. The diagnostic accuracy of the identified risk factors was evaluated using receiver operating curve (ROC). The Kaplan-Meier method with logrank test was utilized to compare the long-term survival of the two groups. A *p* value of less than 0.05 was considered as statistically significant.

# **RESULTS**

Demographic data of current study: A total of 215 patients were included in the present study, including 182 males and 33 females. In the present study, MVI was observed in 41 patients. The mean age was 50.31±10.98 years. The mean tumor size was 3.33±1.05 cm. In current study, the preoperative AFP level of 74 patients was higher than 400 ng/mL. Hypersplenism was observed in 70 patients. The HBV-DNA level of 114 patients was positive in the present study.

Risk factors of microvascular invasion: In the univariate analyses, tumor size, positive HBV-DNA level, preoperative AFP level greater than 400 ng/mL and hypersplenism were potential risk factors for MVI (Table-I). However, in the multivariate study, only tumor size, preoperative AFP level greater than 400 ng/mL and hypersplenism were independent predictors for MVI (Table-II). The ROC curve analysis showed that the best cut-off value of tumor size for identifying MVI was greater than 3.1 cm with 92.93% sensitivity and 52.3% specificity. The area under the ROC curve was 0.716.

A simple preoperative prognostic score was derived from the results of the multivariate analysis. Each above-mentioned risk factor was

Table-I: Univariate analyses of risk factor for MVI.

| Tuble 1. Otherwise analyses of fish factor for wivi. |              |                    |         |  |  |
|--|--------------|--------------------|---------|--|--|
| Variables  | MVI(-) N=174 | <i>MVI(+) N=41</i> | P       |  |  |
| Gender (female)                                      | 28           | 5                  | 0.636   |  |  |
| Age (years)  | 49.79±10.82  | 52.54±11.50        | 0.149   |  |  |
| Tumor size (cm)                                      | 3.20±1.04    | 3.98±0.79          | < 0.001 |  |  |
| Differentiation                                      |              |                    | 0.796   |  |  |
| Well   | 17           | 4                  |         |  |  |
| Moderate   | 88           | 23                 |         |  |  |
| Poor   | 69           | 14                 |         |  |  |
| HBV-DNA (+)  | 87           | 27                 | 0.082   |  |  |
| AFP > 400 ng/mL                                      | 50           | 24                 | < 0.001 |  |  |
| Total bilirubin (µmol/L)                             | 16.01±6.63   | 15.50±6.47         | 0.657   |  |  |
| INR  | 1.06±0.11    | 1.03±0.12          | 0.105   |  |  |
| Albumin (g/L)  | 40.93±6.33   | 42.15±4.59         | 0.343   |  |  |
| Platelet (109/L)                                     | 107.36±48.25 | 114.54±56.95       | 0.410   |  |  |
| AST (U/L)  | 24.77±17.67  | 22.15±7.26         | 0.353   |  |  |
| ALT (U/L)  | 26.75±20.78  | 25.37±15.47        | 0.690   |  |  |
| Prothrombin time (s)                                 | 12.00±1.34   | 11.77±1.50         | 0.343   |  |  |
| Hypersplenism  | 47           | 23                 | 0.001   |  |  |




Fig.1: The recurrence-free (a) and long-term (b) survival curves of all patients.

given a score of 1. If patient had all of the above-mentioned risk factors, the prognostic score was 3; if patient had any two of the 3 independent risk factors, the prognostic score was 2; if patient had any one of the 3 independent risk factors, the prognostic score was 1; if patient didn't have any risk factor, the prognostic score was 0. The ROC curve analysis showed the best cut-off value for the prognostic score was greater than 1 risk factor with 75.6% sensitivity and 75.3% specificity. The area under the ROC curve was 0.790.

Long-term survival comparison of patients with and without MVI: In the present study, recurrence was observed in 95 patients. Of the 95 patients with postoperative recurrence, 38 patients died. The overall 1-, 3-, 5-year recurrence-free survival rates for all patients were 81.9%, 59.9% and 43% respectively (Fig.1a); whereas the overall 1-, 3-, 5-year long-term survival rates for all patients were 98.1%, 83.5% and 68.6% respectively (Fig.1b). The 1-, 3-, 5-year recurrence-free survival rates of group MVI(-) were 82.8%, 62.8% and 48.5% respectively, which were significantly higher than the group MVI(+) (78%, 44.9% and 24.7 respectively; Fig.2a; P=0.025). The 1-, 3-, 5-year long-term survival rates of group MVI(-) were also significantly higher than the group MVI(-) (98.3%, 89.2%, 74.6% versus 80.1%, 46.2%, 46.2%; Fig.2b; *P* < 0.001).




Fig.2: Receiver operating curves for the tumor size
(a) and the predictive risk factors
(b) that were confirmed by multivariate analysis.

Table-II: Multivariate analyses of risk factor for MVI.

| Variables       | Coefficient | OR    | 95% CI      | P       |
|-----------------|-------------|-------|-------------|---------|
| Tumor size (cm) | 0.914       | 2.493 | 1.625-3.825 | < 0.001 |
| AFP > 400 ng/mL | 1.386       | 4.000 | 1.827-8.758 | 0.001   |
| Hypersplenism   | 1.320       | 3.745 | 1.625-3.825 | < 0.001 |

## **DISCUSSION**

MVI is widely accepted as a strong prognostic factor for poor outcomes after liver resection and liver transplantation. For patients with MVI, cancer cells may have disseminated to intrahepatic and/or exhepatic sites via the vascular culture vasculature before liver resection or liver transplantation. Recently, Lim et al. confirmed MVI is a better predictor to Milan criteria in prediction postoperative recurrence after surgical resection for HCC. Their investigation also suggested patients with MVI may suffer from a higher incidence of early recurrence than patients without MVI. In our current study, we also confirmed patients with MVI had an increased risk of postoperative recurrence and reduced long-term survival rate.

Preoperative AFP level was an independent risk factor associated with MVI in the present study. Previous investigations suggested AFP may be a marker of tumor aggressiveness. 12,13 Experimental studies confirmed inhibition of AFP mRNA expression could inhibit the proliferative activity in HCC cell line. 14,15 Recently, Canly et al. 16 suggested AFP-specific immunotherapy could also inhibit the growth of autochthonous hepatocellular carcinoma in mice. This could also explain the correlation of higher AFP level and MVI. AFP was even used to stage HCC or used to select liver transplant candidates.<sup>17</sup> Moreover, a number of investigations have also confirmed higher preoperative AFP level was associated with higher recurrence rate and poor outcomes for patients with HCC.3,18 Graham et al.19 even suggested liver transplantation should offer to patients with small solitary HCC and high preoperative AFP level rather than liver resection.




Fig.3: Recurrence-free (a) and long-term (b) survival comparison of patients with & without MVI.

Consistent with previous studies, our study also confirmed the association between tumor size and MVI.<sup>20</sup> Esnaola et al.<sup>21</sup> suggested tumor size greater than 4 cm was a risk factor for MVI in patients with HCC within Milan criteria who were candidates for liver transplantation. Nagano et al.20 reported tumor sized greater than 7 cm was associated with MVI. Pawlik et al.22 suggested for patients with solitary HCC, tumor size greater than 5 cm significantly predicted MVI. In the present study, the best cut-off value for tumor size was greater than 3.1 cm, which was much smaller than the previous studies. In our study, we only concluded patients with solitary small HCC, whereas large HCC tumors were included in many previous studies. Moreover, the definition of MVI still remains controversial, because some investigators include wall, muscle vessel, or contiguity with the liver parenchyma, whereas others define microvascular invasion as lesions visible only on microscopic examination.<sup>23,24</sup> These reason may explain why our results was much smaller than the previous investigations.

Hypersplenism was another independent risk factor for MVI in our study. A lot of investigations suggested liver resection should not be performed to patients with HCC and hypersplenism because of the high incidence of postoperative recurrence.<sup>25</sup> Our study further suggested patients with hypersplenism had an increased risk of MVI. This result could explain why patients with hypersplenism had a worse outcome than patients without hypersplenism. However, the detail mechanism of the correlation between MVI and hypersplenism is still unclear and needs a further study.

In conclusion, the presence of MVI increased the incidence of postoperative recurrence and reduced the long-term survival rate of patients with HCC. Tumor size, high AFP level and hypersplenism were independent risk factors of MVI for patients with solitary small HCC.

## **REFERENCES**

- Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
- Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, et al. Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg. 2013;17:66-77; discussion: 77
- Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013;119:126-135.
- Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma. ANZ J Surg. 2013;83:331-335.

- Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235-240.
- Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I, et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg. 2010;34:1034-1038.
- Suh YJ, Kim MJ, Choi JY, Park MS, Kim KW. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. Liver Transpl. 2012;18:1171-1178.
- Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108-113.
- Chen XP, Wu ZD, Huang ZY, Qiu FZ. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg. 2005;92:334-339.
- Li C, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ, et al. Outcome of hepatocellular carcinoma treated by liver transplantation: comparison of living donor and deceased donor transplantation. Hepatobiliary Pancreat Dis Int. 2010;9:366-369.
- Furihata T, Sawada T, Kita J, Iso Y, Kato M, Rokkaku K, et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology. 2008;55:1705-1709.
- Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41:431-441.
- Zhang M, Gong Y, Assy N, Minuk GY. Increased GABAergic activity inhibits alpha-fetoprotein mRNA expression and the proliferative activity of the HepG2 human hepatocellular carcinoma cell line. J Hepatol. 2000;32:85-91.
- Li MS, Li PF, He SP, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol. 2002;8:469-475.
- Cany J, Barteau B, Tran L, Gauttier V, Archambeaud I, Couty JP, Turlin B, et al. AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol. 2011;54:115-121.
- Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726-1732.
- Xia Y, Yan ZL, Xi T, Wang K, Li J, Shi LH, et al. A case-control study of correlation between preoperative serum AFP and recurrence of hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology. 2012;59:2248-2254.
- Graham JA, Melancon JK, Shetty K, Johnson LB. Liver transplantation should be offered to patients with small solitary hepatocellular carcinoma and a positive serum alpha fetoprotein rather than resection. Am J Surg. 2013;205:374-380.
- Nagano Y, Shimada H, Takeda K, Ueda M, Matsuo K, Tanaka K, et al. Predictive factors of microvascular invasion in patients with hepatocellular carcinoma larger than 5 cm. World J Surg. 2008;32:2218-2222.
- Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224-232; discussion 232.
- Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086-1092.
- Ataide EC, Boin IFSF, Almeida JRS, Seva-Pereira T, Stucchi RSB, Cardoso AR, et al. Prognostic Factors for Hepatocellular Carcinoma Recurrence: Experience With 83 Liver Transplantation Patients. Transplant Proc. 2011;43:1362-1364.
- 24. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375-1382.
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.